Rate Video

ASH 2018 | AML highlights from ASH 2018

Guillermo Garcia-Manero

ASH 2018

Acute Myeloid Leukemia Leukemia Antibodies Checkpoint inhibitors Pracinostat Venetoclax

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, delivers key highlights, including exciting trials, future outlooks, and developments in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

An update on ASTRAL-3: guadecitabine vs treatment of choice in adults with previously treated MDS

Guillermo Garcia-Manero • 10 Jun 2022

Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent

Guillermo Garcia-Manero • 9 Dec 2017

May the force be with you: the power of next-generation sequencing

Guillermo Garcia-Manero • 9 Dec 2017

Pracinostat for AML update: follow-up analysis and Phase III trial

Guillermo Garcia-Manero • 9 Dec 2017

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig